Abstract:Mutations of isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) genes have been identified as early molecular events in the development of astrocytomas and oligodendrogliomas. Data regarding the status and prevalence of IDH1/2 mutations in Chinese patients are limited. Herein we report our data from West China Hospital, a major Chinese medical centre. IDH1(R132H) mutation was analysed by immunohistochemistry with the mutation-specific IDH1(R132H) antibody in 1011 patients, including 922 central nervous system (CNS) tumours and 89 non-neoplastic CNS lesions, and PCR-based direct sequencing of IDH1/2 gene mutation in 570 of these samples. Correlation with clinicopathological features and immunohistochemical expression of p53, EGFR, PTEN and Ki-67 was examined. Our data showed that IDH1/2 mutation was present in oligodendrogliomas, anaplastic oligodendrogliomas, diffuse or anaplastic astrocytomas, and glioblastomas, with decreasing frequency, but not in other types of CNS tumours or non-neoplastic lesions examined. IDH1(R132) mutation was most frequent in oligodendrogliomas (57/62, 91.9%), with IDH1(R132H) mutation as the most frequent mutation form. Only one case for each of the rare mutations (R132C, R132G, R132L, and R132S) was identified in the 570 samples analysed by sequencing. Younger age, low expression of p53 and low Ki-67 index were significantly correlated with IDH1 mutation status (p = 0.000). All tumours with IDH1(R132) mutations were supratentorial, with frontal lobe as the most frequent site for IDH-mutated gliomas. Only three IDH2(R172) mutation cases were detected in this series. Univariate survival analysis in 459 glioma patients with diffusely infiltrating gliomas showed that IDH1 mutations as well as the more classical prognosticators (age, WHO grade, p53 and Ki-67 index) were of prognostic significance. Multivariate analysis by Cox proportional hazard regression model demonstrated that lack of IDH1 mutation was an independent prognostic factor for both progression-free survival [relative risk (RR) = 2.450, 95% confidence interval (CI) = 1.351-4.444] and diseasespecific survival (RR = 2.489, 95% CI = 1.155-5.363).

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

Prognostic Significance of IDH1 and IDH2 Mutations in Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: a Retrospective Cohort Study and Meta-Analysis.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Mutations in IDH1/2 Genes Predict Better Disease Outcome of Glioma Patients-A Study from Western India

Isocitrate Dehydrogenase (IDH)1/2 Mutations As Prognostic Markers in Patients with Glioblastomas

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

IDH1/2 Gene Hotspot Mutations in Central Nervous System Tumours: Analysis of 922 Chinese Patients

IDH Mutations Associated Impact on Related Cancer Epidemiology and Subsequent Effect Toward HIF-1α

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database

Correlation of IDH1/2 Mutation with Clinicopathologic Factors and Prognosis in Anaplastic Gliomas: a Report of 203 Patients from China

Analysis of Isocitrate Dehydrogenase-1/2 Gene Mutations in Gliomas.

Mutation Analysis Of Idh1 In Paired Gliomas Revealed Idh1 Mutation Was Not Associated With Malignant Progression But Predicted Longer Survival

Prognostic Significance of IDH1 Mutations in Acute Myeloid Leukemia: a Meta-Analysis.

Isocitrate Dehydrogenase Mutation is Associated with Tumor Location and Magnetic Resonance Imaging Characteristics in Astrocytic Neoplasms.

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

Diagnostic and prognostic value of IDH1 mutation in gliomas

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma